Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC) combination therapy met one key secondary endpoint but missed another. The COMPANION-002 study (NCT05506943) evaluated tovecimig, a bispe... See more
Intellia Therapeutics is set to seek US approval of its in vivo CRISPR gene therapy in hereditary angioedema (HAE) after it showed benefit in a Phase III trial. The global Phase III HAELO trial, in which HAE patients were treated with a one-time infusion ... See more
Johnson & Johnson’s (J&J’s) Imaavy (nipocalimab-aahu) has shown continued benefit for two years in patients with generalised myasthenia gravis (gMG) Patients were treated for 24 weeks in the Phase III Vivacity-MG3 and for 96 weeks in the ongoing o... See more
Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety concerns continue to cloud the data. The Swiss-based pharma company previously announced data from the Phase III FENhance 1 (NCT0458601... See more
AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug showed benefit after just 34 weeks, meeting its first primary endpoint. In the Phase III I CAN study (NCT06291376), patients with immunoglobulin A nephropathy (IgA... See more
